ZEN003694
ZEN003694 是目前在国外临床研究中出现的一款新药或疗法，主要研究方向为Squamous Cell Lung Cancer。下面汇总了它当前在全球正在招募患者的研究，以及中国患者可以走的申请途径。
13 项
全球在招研究
0 项
已进入 III/IV 期
2 个
开展国家和地区
有
中国境内设点
药品与企业信息
研发企业
- Memorial Sloan Kettering Cancer Center
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- National Cancer Institute (NCI)
- Zenith Epigenetics
- University of Alabama at Birmingham
- Alexander B Olawaiye, MD
汇总自相关试验登记的主要申办方；研究机构申办时会显示相应机构名称。
生产企业
公开药品批准资料或正式说明书暂未提供明确的生产企业信息。
研发企业与生产企业可能不是同一家。研究阶段药品可能尚未公布生产企业；生产企业仅取自美国上市原研药说明书所列企业（不含仿制药），不作推测；仅在其他国家上市的药品暂无法显示。
主要开展国家和地区
美国、中国
正在招募患者的 ZEN003694 研究
The COSMYC Trial (COmbined Suppression of MYC)
II 期招募中美国NCT06922318Testing the Safety and Efficacy of the Combination of Two Anti-cancer Drugs, ZEN003694 and Abemaciclib, for Adult and Pediatric Patients (12-17 Years) With Metastatic or Unresectable NUT Carcinoma, Breast Cancer and Other Solid Tumors
I 期招募中美国NCT05372640ZEN003694 and Enzalutamide Versus Enzalutamide Monotherapy in Metastatic Castration-Resistant Prostate Cancer
II 期招募中美国中国NCT04986423Trial of Selumetinib and Bromodomain Inhibitor With Durvalumab for Sarcomas
II 期招募中美国NCT05253131Testing the Combination of the Anticancer Drugs ZEN003694 and Binimetinib in Patients With Advanced/Metastatic or Unresectable Solid Tumors With RAS Alterations and Triple Negative Breast Cancer
I 期招募中美国NCT05111561ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancer
II 期招募中美国NCT05071937Testing the Safety and Efficacy of the Addition of a New Anti-cancer Drug, ZEN003694, to Chemotherapy Treatment (Cisplatin and Etoposide or Carboplatin and Paclitaxel) for Adult and Pediatric Patients (12-17 Years) With NUT Carcinoma
I 期 / II 期招募中美国NCT05019716Testing Different Amounts of the Combination of Drugs M1774 and ZEN-3694 for the Treatment of Recurrent Ovarian and Endometrial Cancer
I 期招募中美国NCT05950464Testing the Addition of an Anti-Cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment (Capecitabine) for Metastatic or Unresectable Cancers
I 期招募中美国NCT05803382A Study of ZEN003694 in People With Squamous Cell Lung Cancer
II 期招募中美国NCT05607108Testing the Addition of Anti-Cancer Drug, ZEN003694 (ZEN-3694) and PD-1 Inhibitor (Pembrolizumab), to Standard Chemotherapy (Nab-Paclitaxel) Treatment in Patients With Advanced Triple-Negative Breast Cancer
I 期招募中美国NCT05422794Testing A New Anti-cancer Drug Combination, Entinostat and ZEN003694, for Advanced and Refractory Solid Tumors
I 期 / II 期招募中美国NCT05053971Testing the Addition of Anti-cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment, Cetuximab Plus Encorafenib, for Colorectal Cancer
I 期招募中美国NCT06102902
中国患者怎么争取用上这款药
这款药已经有研究在中国境内设点，可以先带完整病历去对应医院咨询入组；同时也可以并行了解下面几条途径，多一条备选。
查看完整申请指南同类方向的其他在研新药
本页信息整理自 ClinicalTrials.gov 公开登记数据，仅供参考，不构成医疗建议；是否适合使用该药物，请以专业医生和研究团队的意见为准。